Calypte Biomedical Corporation, the developer and marketer of the only two FDA approved HIV-1 antibody tests for use with urine samples, announced that the company has shipped an order of 150,000 HIV-1 EIA tests to its Chinese distributor, Zhong Yang Pute Co. (ZYPute). This order originally announced in June of this year was delayed due to the disruption of normal deliveries to China created by the SARS problem.

"We are pleased to see our product distribution resume to ZYPute in China. This resumption of commerce with China will add to our revenue stream as well as reinforce the commitment to our recent announced Memorandum of Understanding, (MOU) with Marr Technologies Limited for continued expansion into the markets of China," said Tony Cataldo, Calypte's Executive Chairman.

It was previously announced on July 31, 2003, that along with a $2.5 million investment from Marr Technologies Limited, Calypte had signed a Memorandum of Understanding (MOU) regarding the formation of a joint venture in China, with the intent of creating a platform for distribution and sale of Calypte's products in China.